Intersect ENT Stock Price, News & Analysis (NASDAQ:XENT)

$36.05 +0.10 (+0.28 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$36.05
Today's Range$34.95 - $37.28
52-Week Range$12.64 - $38.30
Volume192,929 shs
Average Volume261,596 shs
Market Capitalization$1.06 billion
P/E Ratio-58.15
Dividend YieldN/A
Beta0.78

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:XENT
CUSIPN/A
Phone+1-650-6412100

Debt

Debt-to-Equity RatioN/A
Current Ratio8.47%
Quick Ratio7.87%

Price-To-Earnings

Trailing P/E Ratio-58.1451612903226
Forward P/E Ratio-57.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$78.71 million
Price / Sales13.49
Cash FlowN/A
Price / CashN/A
Book Value$4.00 per share
Price / Book9.01

Profitability

Trailing EPS($0.62)
Net Income$-25,220,000.00
Net Margins-19.81%
Return on Equity-15.96%
Return on Assets-14.16%

Miscellaneous

Employees303
Outstanding Shares29,460,000

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) announced its quarterly earnings data on Thursday, November, 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.05. The medical equipment provider earned $22.31 million during the quarter, compared to analyst estimates of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. Intersect ENT's revenue was up 20.8% on a year-over-year basis. During the same period last year, the firm posted ($0.22) EPS. View Intersect ENT's Earnings History.

When will Intersect ENT make its next earnings announcement?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Intersect ENT.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2018?

10 brokers have issued twelve-month price targets for Intersect ENT's shares. Their forecasts range from $25.00 to $41.00. On average, they anticipate Intersect ENT's share price to reach $33.43 in the next year. View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (1/26/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Intersect following the earlier than expected FDA approval of Sinuva. Specifically, Intersect announced this morning that Sinuva was approved by the FDA with an indication for the treatment of nasal polyps. FDA approval came nearly a month ahead of management guidance and the FDA PDUFA date of January 7, 2018. We previously published a deep dive into the Sinuva product and market opportunity (link here). In sum, the clean approval removes FDA/regulatory overhang headed into YE/17 and positions the company with another meaningful growth driver in 2018 and beyond as Sinuva expands the market opportunity to include stand- alone treatment in the office setting. BUY." (12/11/2017)
  • 3. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

  • Lisa D. Earnhardt, President, Chief Executive Officer, Director (Age 47)
  • Jeryl L. Hilleman, Chief Financial Officer (Age 59)
  • Richard E. Kaufman, Senior Vice President, Chief Operating Officer (Age 55)
  • David A. Lehman, General Counsel (Age 56)
  • Gwen Carscadden, Chief People Officer (Age 55)
  • Kieran T. Gallahue, Lead Director (Age 53)
  • Teresa L. Kline, Director
  • William Anthony Vernon, Director (Age 61)
  • Cynthia L. Lucchese, Independent Director (Age 56)
  • Dana G. Mead Jr., Independent Director (Age 57)

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (7.00%), Jennison Associates LLC (6.91%), BlackRock Inc. (6.72%), Alliancebernstein L.P. (4.98%), Renaissance Technologies LLC (1.08%) and Teachers Advisors LLC (0.98%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Castleark Management LLC, EAM Investors LLC, Deutsche Bank AG, Bogle Investment Management L P DE, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Metropolitan Life Insurance Co. NY and Kopp Investment Advisors LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Teachers Advisors LLC, Alliancebernstein L.P., Renaissance Technologies LLC, Schwab Charles Investment Management Inc., Two Sigma Investments LP, BlackRock Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $36.05.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $1.06 billion and generates $78.71 million in revenue each year. The medical equipment provider earns $-25,220,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Intersect ENT employs 303 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 Adams Dr, MENLO PARK, CA 94025-1439, United States. The medical equipment provider can be reached via phone at +1-650-6412100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (XENT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intersect ENT (NASDAQ:XENT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.782.78
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.43$33.43$30.57$24.88
Price Target Upside: 3.17% upside3.17% upside7.27% upside18.04% downside

Intersect ENT (NASDAQ:XENT) Consensus Price Target History

Price Target History for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ:XENT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2018JPMorgan Chase & Co.UpgradeNeutral -> OverweightHighView Rating Details
12/15/2017GuggenheimReiterated RatingBuy$41.00LowView Rating Details
12/11/2017Canaccord GenuityReiterated RatingBuy$36.00MediumView Rating Details
11/7/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
11/3/2017Northland SecuritiesReiterated RatingHold$25.00N/AView Rating Details
9/11/2017Bank of AmericaBoost Price TargetBuy$33.00 -> $40.00HighView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00LowView Rating Details
8/2/2017Deutsche BankSet Price TargetBuy$27.00 -> $31.00HighView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Intersect ENT (NASDAQ:XENT) Earnings History and Estimates Chart

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ XENT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.17)N/AView Earnings Details
11/2/2017Q3 2017($0.20)($0.15)$21.53 million$22.31 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.19)($0.08)$22.62 million$24.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
9/3/2014Q2 2014($0.28)($2.36)$8.33 million$8.57 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intersect ENT (NASDAQ:XENT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.16)($0.08)($0.12)
Q2 20182($0.12)($0.11)($0.12)
Q3 20182($0.14)($0.11)($0.13)
Q4 20182($0.14)($0.06)($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intersect ENT (NASDAQ XENT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 85.50%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Intersect ENT (NASDAQ XENT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Lisa D EarnhardtInsiderSell15,000$36.40$546,000.00499,683View SEC Filing  
2/6/2018Jeryl L HillemanCFOSell12,833$35.80$459,421.4025,765View SEC Filing  
2/1/2018Richard E KaufmanCOOSell958$37.21$35,647.1887,512View SEC Filing  
1/18/2018Lisa D EarnhardtInsiderSell11,166$33.47$373,726.02495,849View SEC Filing  
1/17/2018Richard E KaufmanCOOSell50,000$33.33$1,666,500.00107,470View SEC Filing  
1/12/2018Gwen R CarscaddenInsiderSell10,000$34.35$343,500.0013,856View SEC Filing  
1/11/2018Jeryl L HillemanCFOSell12,835$33.81$433,951.3525,767View SEC Filing  
12/15/2017Lisa D EarnhardtInsiderSell10,685$31.87$340,530.95487,868View SEC Filing  
12/11/2017David Aaron LehmanGeneral CounselSell36,000$32.75$1,179,000.0045,000View SEC Filing  
12/4/2017Jeryl L HillemanCFOSell12,833$30.06$385,759.9827,833View SEC Filing  
11/20/2017Frederic H MollDirectorSell14,200$28.76$408,392.00247,124View SEC Filing  
11/16/2017Frederic H MollDirectorSell6,700$28.77$192,759.00247,124View SEC Filing  
11/10/2017Frederic H MollDirectorSell800$29.00$23,200.00253,824View SEC Filing  
11/6/2017Jeryl L HillemanCFOSell12,833$27.78$356,500.7427,833View SEC Filing  
10/16/2017Lisa D EarnhardtInsiderSell20,000$28.37$567,400.00View SEC Filing  
10/4/2017Jeryl L HillemanCFOSell12,833$29.96$384,476.68View SEC Filing  
9/25/2017Richard E KaufmanCOOSell13,639$28.97$395,121.83133,757View SEC Filing  
9/15/2017Lisa D EarnhardtInsiderSell20,000$30.19$603,800.00525,868View SEC Filing  
9/5/2017Jeryl L HillemanCFOSell12,833$31.05$398,464.6527,833View SEC Filing  
8/28/2017Richard E KaufmanCOOSell22,425$30.22$677,683.50149,821View SEC Filing  
8/15/2017Lisa D EarnhardtInsiderSell20,000$30.79$615,800.00525,868View SEC Filing  
8/4/2017Jeryl L HillemanCFOSell12,833$29.00$372,157.0027,833View SEC Filing  
7/25/2017Richard E KaufmanCOOSell12,500$28.25$353,125.00169,821View SEC Filing  
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00580,868View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.3027,835View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00583,493View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00182,321View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00600,868View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50202,321View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00610,868View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00620,868View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74194,571View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00557,268View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.1218,076View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.0023,700View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.0027,977View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.0029,000View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.0024,000View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.008,000View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.007,700View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58198,174View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00581,368View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53201,777View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00561,368View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47252,078View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56253,377View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95205,380View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58208,983View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00570,368View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00574,868View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00581,688View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96588,506View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82595,324View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00282,428View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intersect ENT (NASDAQ XENT) News Headlines

Source:
DateHeadline
Intersect ENT Inc (XENT) Expected to Post Quarterly Sales of $29.45 MillionIntersect ENT Inc (XENT) Expected to Post Quarterly Sales of $29.45 Million
www.americanbankingnews.com - February 24 at 10:56 AM
Comparing Intersect ENT (XENT) & Nevro (NVRO)Comparing Intersect ENT (XENT) & Nevro (NVRO)
www.americanbankingnews.com - February 24 at 8:06 AM
Intersect ENT (XENT) and Alliqua Biomedical (ALQA) Critical ReviewIntersect ENT (XENT) and Alliqua Biomedical (ALQA) Critical Review
www.americanbankingnews.com - February 23 at 2:20 PM
 Brokerages Expect Intersect ENT Inc (XENT) to Post -$0.17 EPS Brokerages Expect Intersect ENT Inc (XENT) to Post -$0.17 EPS
www.americanbankingnews.com - February 22 at 3:14 AM
Intersect ENT (XENT) to Release Earnings on MondayIntersect ENT (XENT) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM
Lisa D. Earnhardt Sells 15,000 Shares of Intersect ENT Inc (XENT) StockLisa D. Earnhardt Sells 15,000 Shares of Intersect ENT Inc (XENT) Stock
www.americanbankingnews.com - February 16 at 9:44 PM
Intersect ENT Inc (XENT) Given Average Recommendation of "Buy" by AnalystsIntersect ENT Inc (XENT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 9 at 3:48 AM
Intersect ENT to Report Fourth Quarter and Year 2017 Financial ResultsIntersect ENT to Report Fourth Quarter and Year 2017 Financial Results
finance.yahoo.com - February 8 at 4:15 PM
Intersect ENT Inc (XENT) CFO Jeryl L. Hilleman Sells 12,833 SharesIntersect ENT Inc (XENT) CFO Jeryl L. Hilleman Sells 12,833 Shares
www.americanbankingnews.com - February 8 at 12:30 AM
Insider Selling: Intersect ENT Inc (XENT) COO Sells 958 Shares of StockInsider Selling: Intersect ENT Inc (XENT) COO Sells 958 Shares of Stock
www.americanbankingnews.com - February 5 at 7:16 PM
-$0.17 EPS Expected for Intersect ENT Inc (XENT) This Quarter-$0.17 EPS Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - February 5 at 3:12 AM
Intersect ENT (XENT) Upgraded at BidaskClubIntersect ENT (XENT) Upgraded at BidaskClub
www.americanbankingnews.com - January 27 at 8:42 PM
Intersect ENT (XENT) Raised to Hold at Zacks Investment ResearchIntersect ENT (XENT) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 26 at 3:18 PM
Intersect ENT to Present at the 7th Annual LEERINK Partners Global Healthcare ConferenceIntersect ENT to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
finance.yahoo.com - January 24 at 4:34 PM
Intersect ENT (XENT) Reports Publication of Results for ... - StreetInsider.comIntersect ENT (XENT) Reports Publication of Results for ... - StreetInsider.com
www.streetinsider.com - January 23 at 8:06 AM
Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal PolypsIntersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
finance.yahoo.com - January 22 at 6:00 PM
BidaskClub Downgrades Intersect ENT (XENT) to SellBidaskClub Downgrades Intersect ENT (XENT) to Sell
www.americanbankingnews.com - January 21 at 12:46 PM
Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $29.49 MillionZacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $29.49 Million
www.americanbankingnews.com - January 21 at 8:48 AM
Lisa D. Earnhardt Sells 11,166 Shares of Intersect ENT Inc (XENT) StockLisa D. Earnhardt Sells 11,166 Shares of Intersect ENT Inc (XENT) Stock
www.americanbankingnews.com - January 19 at 9:52 PM
Intersect ENT Inc (XENT) COO Richard E. Kaufman Sells 50,000 SharesIntersect ENT Inc (XENT) COO Richard E. Kaufman Sells 50,000 Shares
www.americanbankingnews.com - January 18 at 9:28 PM
Insider Selling: Intersect ENT Inc (XENT) Insider Sells 10,000 Shares of StockInsider Selling: Intersect ENT Inc (XENT) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - January 16 at 7:08 PM
Intersect ENT Inc (XENT) Receives Consensus Rating of "Buy" from AnalystsIntersect ENT Inc (XENT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 15 at 4:36 AM
Intersect ENT Inc (XENT) CFO Sells $433,951.35 in StockIntersect ENT Inc (XENT) CFO Sells $433,951.35 in Stock
www.americanbankingnews.com - January 12 at 6:58 PM
William Blair Comments on Intersect ENT Incs FY2018 Earnings (XENT)William Blair Comments on Intersect ENT Inc's FY2018 Earnings (XENT)
www.americanbankingnews.com - January 11 at 2:56 PM
Intersect ENT Reports Preliminary Q4 and Year 2017 RevenueIntersect ENT Reports Preliminary Q4 and Year 2017 Revenue
finance.yahoo.com - January 8 at 10:42 AM
 Analysts Anticipate Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $27.58 Million Analysts Anticipate Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $27.58 Million
www.americanbankingnews.com - January 4 at 12:52 PM
-$0.17 Earnings Per Share Expected for Intersect ENT Inc (XENT) This Quarter-$0.17 Earnings Per Share Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - January 2 at 9:28 AM
Intersect ENT (XENT) Upgraded to Overweight at JPMorgan Chase & Co.Intersect ENT (XENT) Upgraded to Overweight at JPMorgan Chase & Co.
www.americanbankingnews.com - January 2 at 8:04 AM
Intersect ENT (XENT) Stock Rating Upgraded by BidaskClubIntersect ENT (XENT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 30 at 12:42 PM
ETFs with exposure to Intersect ENT, Inc. : December 28, 2017ETFs with exposure to Intersect ENT, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:22 PM
Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:13 PM
Intersect ENT (XENT) Lowered to "Sell" at BidaskClubIntersect ENT (XENT) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - December 24 at 12:26 AM
Intersect ENT Inc (XENT) Given Consensus Recommendation of "Buy" by BrokeragesIntersect ENT Inc (XENT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 21 at 3:52 AM
Intersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 10,685 SharesIntersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 10,685 Shares
www.americanbankingnews.com - December 18 at 9:04 PM
$27.58 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter$27.58 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - December 18 at 7:00 AM
Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Announce Earnings of -$0.17 Per ShareZacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - December 16 at 5:12 PM
Intersect ENT (XENT) Given Buy Rating at GuggenheimIntersect ENT (XENT) Given Buy Rating at Guggenheim
www.americanbankingnews.com - December 15 at 7:46 AM
Insider Selling: Intersect ENT Inc (XENT) General Counsel Sells 36,000 Shares of StockInsider Selling: Intersect ENT Inc (XENT) General Counsel Sells 36,000 Shares of Stock
www.americanbankingnews.com - December 13 at 8:58 PM
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval - NasdaqIntersect ENT (XENT) SINUVA Implant Receives FDA Approval - Nasdaq
www.nasdaq.com - December 13 at 10:54 AM
Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent ... - Business Wire (press release)Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent ... - Business Wire (press release)
www.businesswire.com - December 12 at 10:58 AM
Intersect ENTs (XENT) "Buy" Rating Reiterated at Canaccord GenuityIntersect ENT's (XENT) "Buy" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - December 12 at 12:22 AM
Intersect ENT (XENT) Receives FDA Approval of SINUVA Sinus ... - StreetInsider.comIntersect ENT (XENT) Receives FDA Approval of SINUVA Sinus ... - StreetInsider.com
www.streetinsider.com - December 11 at 4:34 PM
Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal PolypsIntersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
finance.yahoo.com - December 11 at 11:13 AM
Intersect ENT (XENT) Cut to "Hold" at BidaskClubIntersect ENT (XENT) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - December 10 at 10:40 AM
Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : December 6, 2017Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : December 6, 2017
finance.yahoo.com - December 6 at 10:49 AM
Zacks: Brokerages Anticipate Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $27.58 MillionZacks: Brokerages Anticipate Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $27.58 Million
www.americanbankingnews.com - November 30 at 11:22 AM
STAAR Surgical (STAA) & Intersect ENT (XENT) Critical ComparisonSTAAR Surgical (STAA) & Intersect ENT (XENT) Critical Comparison
www.americanbankingnews.com - November 28 at 3:50 AM
Intersect ENT, Inc. (XENT) Receives Consensus Rating of "Buy" from BrokeragesIntersect ENT, Inc. (XENT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 26 at 4:14 AM
Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : November 24, 2017Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : November 24, 2017
finance.yahoo.com - November 24 at 6:37 PM
Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : November 23, 2017Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : November 23, 2017
finance.yahoo.com - November 23 at 6:23 PM

SEC Filings

Intersect ENT (NASDAQ:XENT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intersect ENT (NASDAQ:XENT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intersect ENT (NASDAQ XENT) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.